More on BAYRY
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $9.94 |
|
|||
| Open | $10.26 | ||||
| 52 Wk High | $135.54 | ||||
| 52 Wk Low | $94.36 | ||||
| Day High | $10.29 | ||||
| Day Low | $10.23 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 145,007 | ||||
- Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
- Barclays on Bayer AG (BAYN:GR) (BAYRY): 'Conditional transfer of settlement to federal level adds noise'
- ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
- UBS Reiterates Buy Rating on Bayer AG (BAYN:GR) (BAYRY)
- Morgan Stanley continues to see "material upside" in this big pharma stock
- Bayer to present cancer trial data at ASCO 2026 meeting
- ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
- Bayer's KERENDIA gets FDA priority review for type 1 diabetes treatment
- Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
- Bayer AG (BAYN:GR) (BAYRY) PT Raised to EUR50 at Barclays
Entities mentioned with BAYRY
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Credit Suisse | View Related Stories »
- Show More...
